The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 26, Issue 1, 2008, Pages 34-41

  Ding, Hansheng ^a,b   Koinuma, Nobuo ^a   Stevenson, Matt ^c   Ito, Michiya ^a   Monma, Yasutake ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost effectiveness analysis; Fracture; Japan; Osteoporosis; Risedronate

Indexed keywords

ALFACALCIDOL; CALCIUM; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCULATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; FEMALE; FRACTURE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MEDICAL LITERATURE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; JAPAN; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 37349081250     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0794-4     Document Type: Article

References (45)

1. Kishimoto H (2005) Change in the definition of osteoporosis especially on bone quality. Clin Calcium 15:736-740
2. Anonymous (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1-6
3. Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650
4. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368-381
5. Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192-202
6. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone (NY) 34:195-202
7. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
8. Ray NF, Chan JK, Thamer M, Melton LJ III (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
9. Melton LJ III (1993) Hip fractures: a worldwide problem today and tomorrow. Bone (NY) 14(suppl 1):S1-S8
10. Hayashi Y (2004) Health economics of treatment of osteoporosis (in Japanese). Geriatr Med 42:613-618
11. Lindsay R (1995) The burden of osteoporosis: cost. Am J Med 98:9S-11S
12. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RG, Stevenson JC (1998) Management of male osteoporosis: report of the UK Consensus Group. Q J Med 91:71-92
13. Cummings SR, Rubin SM, Black D (1990) The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop Relat Res 252:163-166
14. http://www.nice.org.uk/pdf/TAP_Methods.pdf
15. Whang W, Sisk JE, Heitjan DF, Moskowitz AJ (1999) Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly. Int J Technol Assess Health Care 15:563-572
16. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37
17. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
18. Levy P, Levy E, Audran M, Cohen-Solal M, Fardellone P, Le Parc JM (2002) The cost of osteoporosis in men: the French situation. Bone (NY) 30:631-636
19. Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W (1999) Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 21:2001-2014
20. Martin BC, Chisholm MA, Kotzan JA (2001) Isolating the cost of osteoporosis-related fracture for postmenopausal women. A population-based study. Gerontology 47:21-29
21. MHLW (2004) Patient Survey 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo, p. 684
22. http://wwwdbtk.mhlw.go.jp/IPPAN/ippan/scm_k_Ichiran
23. MHLW (2004) Patient Survey 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo, p. 49
24. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547-1553
25. Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469-478
26. Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14:225-234
27. Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K (2006) Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab 24:105-113
28. Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743-1748
29. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
30. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
31. Institute SIR (2006) Remuneration Standard for Medical Services, version 4. Japan Social Insurance Research Institute, Tokyo, p. 162
32. Jibou (2004) National Health Insurance Price List (in Japanese). Jibou Press, Tokyo
33. Stevenson MD, Davis S (2005) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. http://wwwniceorguk/pageaspx?o=370643. Accessed 2006/12/12
34. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971-979
35. Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488-495
36. MHLW (2004) Social medical insurance reimbursement survey 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo
37. MHLW (2004) Report of long-term care insurance payment 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo
38. Rahman M, Sekimoto M, Takamatsu I, Hira K, Shimbo T, Toyoshima K, Fukui T (2001) Economic evaluation of universal BCG vaccination of Japanese infants. Int J Epidemiol 30:380-385
39. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721
40. Kurimori S, Fukuda Y, Nakamura K, Watanabe M, Takano T (2006) Calculation of prefectural disability-adjusted life expectancy (DALE) using long-term care prevalence and its socioeconomic correlates in Japan. Health Policy 76:346-358
41. Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23:167-173
42. MHLW (2004) Patient survey 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo, pp 430-431, 472-473
43. MHLW (2004) Patient survey 2002 (in Japanese). Health and Welfare Statistics Association, Tokyo, pp 434-435, 476-477
44. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
45. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26